Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:29:26 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Z:IBIO - IBIO INC - http://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Z0.11.60·1.910.11.76+0.042.360.2922391.77  1.80  1.7223.60  1.021418:10:47Mar 2715 min RT 2¢

Recent Trades - Last 10 of 239
Time ETExPriceChangeVolume
18:10:47Z1.780.061
18:09:43Z1.780.0612
17:22:23Z1.780.0620
15:58:23Z1.7650.0451
15:55:29Z1.760.04100
15:55:29Z1.760.0454
15:53:27Z1.770.0518
15:51:22Z1.79920.0792100
15:50:17Z1.800.0831
15:47:56Z1.790.073

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-27 07:00U:IBIONews ReleaseiBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
2024-03-26 19:35U:IBIONews ReleaseiBio Announces $15.0 Million Private Placement
2024-02-26 07:45U:IBIONews ReleaseiBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
2024-01-16 08:15U:IBIONews ReleaseiBio Announces Participation in 23rd Annual PepTalk Conference
2023-12-26 07:15U:IBIONews ReleaseiBio Amends and Extends Maturity of Credit Agreement
2023-12-05 08:00U:IBIONews ReleaseiBio, Inc. Announces Pricing of $4.5 Million Public Offering
2023-11-27 17:20U:IBIONews ReleaseiBio Announces Reverse Stock Split
2023-11-01 08:24U:IBIONews ReleaseiBio Further Expands Tech Stack with ShieldTx ¢ „ ¢; Enhances Immuno-Oncology ‚  Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
2023-10-10 08:00U:IBIONews ReleaseiBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
2023-10-02 06:45U:IBIONews ReleaseiBio Explains Recent Filing of Registration Statement
2023-09-27 16:19U:IBIONews ReleaseiBio Announces Filing of 2023 Annual Report on SEC Form 10-K
2023-09-21 16:05U:IBIONews ReleaseiBio Announces Amendment to Credit Agreement with Woodforest
2023-08-14 16:15U:IBIONews ReleaseiBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
2023-06-27 08:00U:IBIONews ReleaseiBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company ¢ € ™s Next Stage of Growth
2023-06-12 16:15U:IBIONews ReleaseiBio Forges Research Collaboration with the National Institutes of Health
2023-06-06 08:00U:IBIONews ReleaseiBio Expands Tech Stack with EngageTx ¢ „ ¢; Adds TROP-2 Bispecific to Development Pipeline
2023-05-09 16:30U:IBIONews ReleaseiBio to Participate in the JMP Securities Life Sciences Conference